Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965814 | 0.94 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKDM4EPOLB | |
| SCHEMBL3227271 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRKDM4EPOLB | |
| SCHEMBL3231744 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRKDM4EPOLB | |
| SCHEMBL3213698 | 0.88 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TSHRKDM4EPOLB | |
| SCHEMBL3220490 | 0.83 | KMT2A (0.49) | ALDH1A1KDM4EPOLBHPGDHTT | |
| SCHEMBL3219335 | 0.81 | POLB (0.52) | POLBHTTKMT2ALMNAMEN1 | |
| SCHEMBL3231891 | 0.81 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2TSHRKDM4EPOLB | |
| SCHEMBL3219867 | 0.80 | THRB (0.40) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL3224429 | 0.80 | THRB (0.38) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL3223456 | 0.78 | HSP90AA1 (0.48) | ALDH1A1POLBHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420851-B2 | Selective TR-β 1 agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-04-16 | — | — | US | claimed |
| EP-2079678-B1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LTD (IN) | 2012-12-19 | — | — | EP | claimed |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-02-25 | — | — | US | claimed |
| US-8420851-B2 | Selective TR-β 1 agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2079678-B1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LTD (IN) | 2012-12-19 | — | — | EP | disclosed |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-02-25 | — | — | US | disclosed |
| EP-2079678-A2 | SELECTIVE TR-BETA 1 AGONIST | Cadila Healthcare Limited (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008062469-A2 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | THRB, THRA, TSHR | ALDH1A1 1801/4885SMN1; SMN2 4010/4885TSHR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.